Zucara Therapeutics, a diabetes-focused life sciences company developing the first once-daily use therapeutic to prevent hypoglycemia in people with diabetes, recently announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug (IND) application for ZT-01 for the prevention of nocturnal hypoglycemia in patients with Type 1 Diabetes.
Zucara presented at the OBIO® Investment Summit and is part of Workforce Development.